Generation Bio to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Generation Bio Co. (Nasdaq: GBIO) announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021. CEO Geoff McDonough will share insights on the company’s progress and upcoming milestones. Recently, Generation Bio achieved a key scientific milestone by demonstrating human factor VIII expression in hemophilia A mice, reaching 23% of normal levels. They also confirmed the successful translation of their liver-targeted delivery system into non-human primates, supporting further studies for hemophilia A treatments.

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that the company will present at the virtual 39^th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021.

President and Chief Executive Officer Geoff McDonough, M.D., will provide an overview of the company’s progress and anticipated milestones for 2021.

Generation Bio this week announced a scientific milestone with the first demonstration of a non-viral gene therapy platform enabling human factor VIII expression in mice with hemophilia A. Mean levels of factor VIII reached 23% of normal levels.

The company also announced data confirming successful translation of the company’s liver-targeted lipid nanoparticle delivery system into non-human primates. Together, the data support the advancement of Generation Bio’s lead program in hemophilia A into IND-enabling studies.

Presentation Details
Date: Tuesday, Jan. 12, 2021
Time: 2:50-3:30 p.m. ET

A live webcast of the company presentation and Q&A session will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio

Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.

For more information, please visit www.generationbio.com. 

Contact:

Investors 
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420

Media 
Alicia Webb
Generation Bio
awebb@generationbio.com
847-254-4275

Stephanie Simon 
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

FAQ

When is Generation Bio's presentation at the J.P. Morgan Healthcare Conference?

Generation Bio will present on January 12, 2021.

What significant milestone did Generation Bio recently achieve?

Generation Bio demonstrated human factor VIII expression in mice with hemophilia A, reaching 23% of normal levels.

What time will Generation Bio's presentation take place?

The presentation is scheduled from 2:50 to 3:30 p.m. ET.

How can I access the live webcast of Generation Bio's presentation?

The live webcast will be available on Generation Bio's investor website.

What is the focus of Generation Bio's recent research?

The focus is on developing non-viral gene therapies for hemophilia A.